Background: Rucaparib (CO-338) is an oral small molecule inhibitor of poly (ADP-ribose) polymerase (PARP) that is being developed for patients with BRCA1 and BRCA2 mutated and homologous recombination ...

1Laboratory of Rare Human Circulating Cells (LCCRH), University Medical Centre of Montpellier, Montpellier, France.

Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain. Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona (UB), ...

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Department of Medicine, Brigham and Women's Hospital, and Department of Medicine, Harvard Medical School, Boston, ...

1AstraZeneca, ICC, Early Oncology, R&D, Cambridge, United Kingdom.

1Yonsei University, College of Medicine, Seoul, Republic of Korea.

Cancer Res (2023) 83 (7_Supplement): ND02.

1Whitehead Institute for Biomedical Research, Cambridge, Massachusetts. 2Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts. 3Ludwig MIT Center for Molecular ...

1Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland. *Corresponding Author: Cari M. Kitahara, Division of ...

1Department of Oncology, University of Lausanne, Lausanne, Switzerland.

1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

1Novelty Nobility, lnc., Seongnam-si, Republic of Korea.